Company Filing History:
1 out of 31 
1 out of 338 
Years Active: 2020
Title: The Innovative Contributions of Ryotaro Nishi
Introduction
Ryotaro Nishi is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative research and patent applications. His work focuses on exploiting synthetic lethality and chemo-sensitization in DNA damage response pathways.
Latest Patents
Nishi holds a patent for "Methods of screening and treatment with USP4 inhibitors." This patent relates to materials and methods for utilizing synthetic lethality and/or chemo-sensitization in DNA damage response pathways. Specifically, it addresses the ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its role in DNA damage response pathways. The patent describes the use of USP4 inhibitors in cancer treatment, particularly for tumors that are defective in double-strand break repair and those resistant to platinum-based chemotherapy.
Career Highlights
Throughout his career, Ryotaro Nishi has worked with various organizations, including Mission Therapeutics Limited and Cambridge Enterprise Limited. His experience in these companies has allowed him to advance his research and contribute to the development of innovative cancer therapies.
Collaborations
Nishi has collaborated with notable colleagues such as Xavier Jacq and Helen Robinson. These partnerships have further enhanced his research efforts and contributed to the advancement of cancer treatment methodologies.
Conclusion
Ryotaro Nishi's work in the field of cancer treatment through his patent on USP4 inhibitors showcases his innovative spirit and dedication to improving therapeutic options for patients. His contributions are significant in the ongoing fight against cancer.